Storia in 2 fonti

Nonprofit buys experimental cancer drug to maintain patient access

In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational cancer drug.

Raccontata da

morningstar.com

statnews.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

statnews.comStai leggendo1 mese fa

Nonprofit buys experimental cancer drug to maintain patient access

Blood Cancer United acquired Luvelta (ADC, pediatric AML) after Sutro's March 2025 discontinuation, operating free program for ~20 patients. Signals rare-disease market failure: small volumes lack ROI, forcing nonprofits to bridge—pattern with AI-driven niche discovery.

originale

morningstar.com1 mese fa

Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal…

Blood Cancer United acquires luveltamab for pediatric AML (17 cases/year, 15-30% survival) abandoned by pharma due to poor commercial prospects. Market failure in rare-disease therapeutics: when patient bases are tiny, commercial incentives vanish and nonprofits must preserve access.

Timeline cronologica

giovedì 11 giugno 2026·morningstar.com
Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia
Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia
giovedì 11 giugno 2026·statnews.com
Nonprofit buys experimental cancer drug to maintain patient access
In a rare move, nonprofit organization Blood Cancer United is buying the remaining supplies of a discontinued investigational cancer drug.

Nonprofit buys experimental cancer drug to maintain patient access

Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal…

Timeline cronologica

Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia

Nonprofit buys experimental cancer drug to maintain patient access

Pharmalittle: We're reading about a discontinued cancer drug, a Novo security breach, and more